Cargando…

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.

The tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid (DMXAA) causes dramatic haemorrhagic necrosis in murine tumours, but activity is seen only at doses close to the toxic limit. This study investigates two approaches for increasing the therapeutic ratio of DMXAA. The first approach...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lash, C. J., Li, A. E., Rutland, M., Baguley, B. C., Zwi, L. J., Wilson, W. R.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063102/ https://www.ncbi.nlm.nih.gov/pubmed/9716024

Ejemplares similares

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
por: Jameson, M B, et al.
Publicado: (2003)

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
por: Rustin, G J S, et al.
Publicado: (2003)

Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
por: Ching, L-M, et al.
Publicado: (2002)

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
por: Zhao, L, et al.
Publicado: (2002)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
por: Ching, L. M., et al.
Publicado: (1995)

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.
por: Ching, L. M., et al.
Publicado: (1992)

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
por: Ching, L-M, et al.
Publicado: (2004)

Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
por: Cao, Z, et al.
Publicado: (1999)

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
por: Laws, A. L., et al.
Publicado: (1995)

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
por: Philpott, M., et al.
Publicado: (1997)

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
por: Ching, L. M., et al.
Publicado: (1998)

Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
por: Moilanen, E., et al.
Publicado: (1998)

Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid.
por: Zwi, L. J., et al.
Publicado: (1990)

Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach
por: Pan, Shu-Ting, et al.
Publicado: (2015)

5- Hydroxytryptamine
por: Giarman, Nicholas J.
Publicado: (1958)

Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).
por: Chaplin, D. J.
Publicado: (1986)

Bioreductive drugs and the selective induction of tumour hypoxia.
por: Bremner, J. C., et al.
Publicado: (1990)

The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels.
por: Zwi, L. J., et al.
Publicado: (1990)

STORAGE OF 5-HYDROXYTRYPTAMINE IN MEGAKARYOCYTES
por: Tranzer, J. P., et al.
Publicado: (1972)

Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells
por: Rauca, Valentin-Florian, et al.
Publicado: (2018)

Inflammatory changes in tumour vessels after systemic 5-hydroxytryptamine, bradykinin, kallikrein, or lysolecithin.
por: Cater, D. B., et al.
Publicado: (1966)

Mammary Tumour Development in BR6 Mice: Ovarian Influences and 5-Hydroxytryptamine
por: Lee, Audrey E.
Publicado: (1970)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
por: Robinson, S P, et al.
Publicado: (2003)

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
por: Patterson, L H, et al.
Publicado: (2000)

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
por: Wang, J., et al.
Publicado: (1993)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
por: Pozhidaev, Ivan V., et al.
Publicado: (2020)

Serotonin in the rat prefrontal cortex controls the micturition reflex through 5‐hydroxytryptamine 2A and 5‐hydroxytryptamine 7 receptors
por: Chiba, Hiroki, et al.
Publicado: (2020)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Physiological Control of Molluscan Gill Cilia by 5-Hydroxytryptamine
por: Gosselin, R. E., et al.
Publicado: (1962)

CHEMICAL AND ULTRASTRUCTURAL IDENTIFICATION OF 5-HYDROXYTRYPTAMINE IN AN IDENTIFIED NEURON
por: Rude, Sonia, et al.
Publicado: (1969)

5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials
por: Pithadia, Anand B., et al.
Publicado: (2009)

The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine
por: Liu, Ning, et al.
Publicado: (2021)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
por: Peng, Shiwen, et al.
Publicado: (2011)

Phylogenetic analyses of 5-hydroxytryptamine 3 (5-HT(3)) receptors in Metazoa
por: Rao, Santosh T. R. B., et al.
Publicado: (2023)

Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
por: Butler, S. A., et al.
Publicado: (1997)

Effects of 5-hydroxytryptamine on spermatozoal hyperactivation and in vitro fertilization in mice
por: SUGIYAMA, Yukiko, et al.
Publicado: (2019)

5-Hydroxytryptamine, Glutamate, and ATP: Much More Than Neurotransmitters
por: Franco, Rafael, et al.
Publicado: (2021)

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
por: Friery, O P, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_lkekokqfrl7re87ij24kosjgva